Shots:
- BMS has reported the 28wk. P-III (SCOUT-HCM) trial data assessing Camzyos (mavacamten) vs PBO in 44 pts (12 to <18yrs.) with symptomatic oHCM & NYHA class II-III symptoms, with plans to present 56wk. data in a future conference
- Trial met its 1EP, showing reductions in Valsalva LVOT gradient at Wk. 28, supported by more pts achieving <30 mm Hg maximal LVOT gradient, & also showed improved resting & post-exercise LVOT gradients (2EP) at Wk. 28
- Camzyos also demonstrated positive structural changes vs PBO, with reduced maximal LV wall thickness & improved diastolic function via lower E/e’ ratio; data will be presented at the ACC Annual Scientific Session & Expo 2026, & published in The NEJM
Ref: BMS | Image: BMS | Press Release
Related News: insitro and Bristol Myers Squibb Collaborate to Advance Drug Discovery for Amyotrophic Lateral Sclerosis (ALS)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
